Jade Biosciences, Inc. (JBIO): Total Liabilities
$17.26M
As of 2025-12-31
$32.20M
As of 2026-06-30
+26.4%
3-year compound annual growth
+57.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.26M | -85.6% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $119.60M | +565.8% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $17.96M | +109.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $8.56M | +190.6% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $2.94M | +66.0% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $1.77M | n/a | 2022-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | 2025-12-31 | $17.26M | -85.6% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $78.03M | -37.2% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $14.00M | +18.0% |
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | $50.16M | +100.5% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $91.85M | -15.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $17.28M | -2.3% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $25.95M | +50.1% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $27.39M | -5.1% |
Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗